KRAS G12D Inhibitor MRTX1133

Preferred Label : KRAS G12D Inhibitor MRTX1133;

NCIt synonyms : KRAS-G12D Inhibitor MRTX1133;

NCIt related terms : MRTX-1133;

NCIt definition : An orally bioavailable reversible inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor MRTX1133 specifically targets and noncovalently binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.;

UNII : DU32DM9CHD;

CAS number : 2621928-55-8;

Molecule name : MRTX 1133; MRTX1133; MRTX -133;

NCI Metathesaurus CUI : CL1907132;

Détails

Origin ID

C200319;

UMLS CUI

C5772099;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- KRASG12D inhibitor MRTX1133 [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- KRAS NP_004976.2:p.G12D [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients